Aventis Pharmaceuticals, Inc.
(A subsidiary of Aventis S.A.)
300 Somerset Corporate Boulevard
About Aventis Pharmaceuticals, Inc.Hoechst Marion Roussel and Rhone-Poulenc Rorer have adopted the name Aventis Pharmaceuticals to create: A new world class leader in the pharmaceutical industry.
From the start, Aventis Pharmaceuticals will have the resources to become a leader in today's highly competitive pharmaceutical industry: one of the world's largest research and development budgets, commercial strengths in all of the world's major markets, experienced international management and an outstanding workforce. This 13 billion euro giant ranks among the leaders worldwide in prescription drug sales, has a sales force with proven effectiveness, and a robust market presence around the world.
Our mission is to generate a continuous flow of significant therapies to support the competitiveness and growth of Aventis by:
What most pharmaceutical companies call Research and Development will look much different at Aventis Pharmaceuticals. The company is pursuing a “new paradigm” to organize all of the global functions- from discovery of new molecules, through preclinical and clinical studies and on to regulatory efforts into a single organization called Drug Innovation and Approval.
Located in the heart of the world's largest and fastest-growing healthcare market, the Aventis Pharmaceutical Global Drug Development Center (GDDC) in Bridgewater, New Jersey provides a strategic center for key global activities and teams.
The GDDC concept is designed to enhance information sharing, responsiveness, resource optimization, regulatory strategies and outsourcing flexibility. Specifically, the Bridgewater GDDC enhances Aventis Pharmaceuticals’ operations through:
DI&A Discovery Research includes (in the U.S): Immunology Platform Respiratory Diseases Rheumatoid Arthritis CNS/neuropsychiatric and neuroinflammatory disorders Lead Generation High Throughput Screening Medicinal Chemistry Physical Chemistry Automated Synthesis
DI&A Global Functions include: Pharmacovigilance Product Realization (Clinical Research) Lead Optimization Drug Regulatory Affairs
Strategic Brands The products of Aventis Pharma improve the lives of millions of patients around the world. Among the currently marketed brands, Aventis Pharma's five major growth drivers already are contributing to improving financial performance.
Click to view strong growth drivers
Last Updated 5/8/00
16 articles with Aventis Pharmaceuticals, Inc.
Cortria Corporation Appoints Dennis H. Giesing, Ph.D., Former Worldwide Head of Lead Optimization at Aventis Pharmaceuticals, Inc., as Head of Research and Development
International Genomics Consortium Release: Expression Project For Oncology Completes First Phase Of Standardized Gene Expression Analyses
Sanofi-Aventis Group Release: Taxotere(R) (Docetaxel) Regimen Significantly Improves Survival In Women With Node Positive Early Stage Breast Cancer
Columbia University Medical Center Release: Breast Cancer Drug Taxotere(R) Extends Life Of Prostate Cancer Patients
The Sanofi-Aventis Group Thanks Its Team Members And Shareholders And Launches Its New Visual Identity